Robyn Hunter
Director/Board Member at TENAX THERAPEUTICS, INC.
Net worth: - $ as of 29/04/2024
Robyn Hunter active positions
Companies | Position | Start | End |
---|---|---|---|
TENAX THERAPEUTICS, INC. | Director/Board Member | 27/01/2022 | - |
Independent Dir/Board Member | 27/01/2022 | - | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Director of Finance/CFO | 31/07/2022 | - |
Career history of Robyn Hunter
Former positions of Robyn Hunter
Companies | Position | Start | End |
---|---|---|---|
FORTRESS BIOTECH, INC. | Comptroller/Controller/Auditor | 31/07/2011 | 25/06/2017 |
Director of Finance/CFO | 25/06/2017 | 15/08/2022 | |
Corporate Secretary | 31/05/2011 | 15/08/2022 | |
Treasurer | 31/05/2011 | 15/08/2022 | |
Schochet Associates, Inc. | Director of Finance/CFO | 31/12/2005 | 30/04/2011 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Comptroller/Controller/Auditor | 31/07/2004 | 31/12/2005 |
Stackpole Corp. | Treasurer | 31/12/1989 | 31/12/2003 |
MUSTANG BIO, INC. | Corporate Secretary | - | - |
Treasurer | - | - | |
AVENUE THERAPEUTICS, INC. | Corporate Secretary | - | - |
CHECKPOINT THERAPEUTICS, INC. | Corporate Secretary | - | - |
Training of Robyn Hunter
Union College (New York) | Undergraduate Degree |
Statistics
International
United States | 9 |
Canada | 2 |
Czech Republic | 2 |
Operational
Corporate Secretary | 4 |
Director of Finance/CFO | 3 |
Treasurer | 3 |
Sectoral
Health Technology | 8 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 5 |
---|---|
CHECKPOINT THERAPEUTICS, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
MUSTANG BIO, INC. | Health Technology |
TENAX THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Stackpole Corp. | Producer Manufacturing |
Schochet Associates, Inc. | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
- Stock Market
- Insiders
- Robyn Hunter
- Experience